LDLR and homozygous familial hypercholesterolemia: As stated previously, it is important to differentiate HoFH from HeFH because of the following: 1) novel therapies whose mechanisms are independent of LDLR pathway are available in patients with HoFH; 2) there are some complications that are quite specific and in patients with HoFH; and 3) LDL-lowering therapies, including the ones stated previously, need to be introduced as soon as possible in patients with HoFH, compared with the situation where LDL-lowering therapies are recommended to be introduced at age 8 to 10 years in patients with HeFH.